Effect of Lipopolysaccharide on Skeletal Muscle Functions (LPS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigators aim to examine how the skeletal muscles of the human volunteers respond to experimental septic conditions to aid understanding of muscle wasting and its biology..
Six healthy men aged 18-30 will be randomly assigned to two metabolic study visits. On the first visit, while resting on a bed, they will have four cannulae inserted including one in the upper thigh, for blood sampling and the infusion of insulin, glucose and normal and tracer amino acids (which allow us to measure muscle protein metabolism). Subjects will receive either injection of purified bacterial product called lipopolysaccharide (LPS) to induce flu-like symptoms or normal saline according to randomization followed by a metabolic test to stimulate muscle synthesis and glucose transport. Three small samples of muscle will be obtained under local anaesthetic from the thigh to measure molecular events in muscle. By performing these measurements, the investigators will determine the consequences of LPS on muscle production and carbohydrate metabolism.
| Condition | Intervention |
|---|---|
|
Sepsis |
Biological: Lipopolysaccharide infusion |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Basic Science |
| Official Title: | Impact & Time-Course of Effect of Intravenous Lipopolysaccharide Infusion on Skeletal Muscle Protein Turnover and Insulin Sensitivity in Healthy Human Volunteers |
- Skeletal Muscle Protein Turnover (muscle tracer incorporation) [ Time Frame: 4 hr following LPS infusion ] [ Designated as safety issue: No ]
- Whole body glucose disposal [ Time Frame: 4 h Glucose insulin clamp ] [ Designated as safety issue: No ]
- Expression of genes that regulate muscle protein balance and insulin signalling [ Time Frame: 4 h following LPS infusion ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 8 |
| Study Start Date: | July 2011 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
-
Biological: Lipopolysaccharide infusion
During sepsis, the ability of the body to prevent muscle wasting is impaired resulting in loss of skeletal muscle. In addition, skeletal muscle handling of carbohydrate becomes less efficient. These changes could result in delayed recovery, prolonged rehabilitation and in severe cases mortality of patients. It is still unclear how these changes occur in the human skeletal muscles but animal experiments suggest that protein molecules that are released during sepsis are responsible for these changes. Due to the biological differences between animals and humans in metabolic rate and stability, disease susceptibility and response to infection, simple translation of knowledge from animals to patients could be highly misleading. Therefore, we aim to examine how the skeletal muscles of the human volunteers respond to experimental septic conditions.
Following medical screening, six healthy men aged 18-30 will have two metabolic study visits in a random manner. On the first visit, while resting on a bed, they will have four cannulae inserted including one in the upper thigh, for blood sampling and the infusion of insulin, glucose and normal and tracer amino acids (which allow us to measure muscle protein metabolism). Subjects will receive either injection of purified bacterial product called lipopolysaccharide (LPS) to induce flu-like symptoms or normal saline according to randomization followed by a metabolic test to stimulate muscle synthesis and glucose transport. Three small samples of muscle will be obtained under local anaesthetic from the thigh to measure molecular events in muscle. By performing these measurements, we will determine the consequences of LPS on muscle production and carbohydrate metabolism.
Eligibility| Ages Eligible for Study: | 18 Years to 30 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Male 18-30yrs
Exclusion Criteria:
Clotting disorders Metabolic disease e.g. diabetes, thyroid dysfunction Inflammatory conditions e.g. Crohn's Disease Tobacco smoker Cardiac or Renal pathology Respiratory problems including Asthma Active infectious conditions
Contacts and Locations| Contact: Kanagaraj Marimuthu, MS, MRCS | 01158230199 | kanagaraj.marimuthu@nottingham.ac.uk |
| Contact: Paul Greenhaff, PhD | 01158230133 | paul.greenhaff@nottingham.ac.uk |
| United Kingdom | |
| Queens Medical Centre | Recruiting |
| Nottingham, Nottinghamshire, United Kingdom, NG7 2UH | |
| Contact: Kanagaraj Marimuthu, MS, MRCS kanagaraj.marimuthu@nottingham.ac.uk | |
| Sub-Investigator: Kanagaraj Marimuthu, MS, MRCS | |
| Principal Investigator: Paul Greenhaff, PhD | |
| Sub-Investigator: Dileep N Lobo, MS, DM, FRCS | |
| Sub-Investigator: Ravi Mahajan, MD, DM, FRCA | |
| Principal Investigator: | Paul L Greenhaff, PhD | Professor of Muscle Metabolism, University of Nottingham |
More Information
No publications provided
| Responsible Party: | University of Nottingham |
| ClinicalTrials.gov Identifier: | NCT01423968 History of Changes |
| Other Study ID Numbers: | B/12/2010 |
| Study First Received: | August 11, 2011 |
| Last Updated: | December 3, 2012 |
| Health Authority: | United Kingdom: Research Ethics Committee |
Keywords provided by University of Nottingham:
|
Sepsis Inflammation Lipopolysaccharide Muscle protein turnover Insulin resistance |
Additional relevant MeSH terms:
|
Sepsis Infection Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes |
ClinicalTrials.gov processed this record on May 19, 2013